Principles for designing future regimens for multidrug-resistant tuberculosis;Principes de conception de futurs schémas thérapeutiques pour traiter la tuberculose multirésistante

Bulletin of the World Health Organization

Volumn 92, Issue 1, 2014, Pages 68-74

  Brigden, Grania ^a   Nyang'wa, Bern Thomas ^a   du Cros, Philipp ^a   Varaine, Francis ^a   Hughes, Jennifer ^a   Rich, Michael ^b   Horsburgh Jr , C Robert ^c   Mitnick, Carole D ^d   Nuermberger, Eric ^e   McIlleron, Helen ^f   Phillips, Patrick P J ^g   Balasegaram, Manica ^a  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b PARTNERS IN HEALTH   (United States)

^c BOSTON UNIVERSITY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

^g MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6, 7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO [2, 1 B] [1, 3] OXAZINE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AZD 5847; BEDAQUILINE; CLOFAZIMINE; DELAMANID; LINEZOLID; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; OXAZOLIDINONE DERIVATIVE; SUTEZOLID; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE; QUINOLINE DERIVATIVE;

ARTICLE; BACTERICIDAL ACTIVITY; DRUG ANTAGONISM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEARING IMPAIRMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; LIVER FAILURE; MIXED INFECTION; MULTICENTER STUDY (TOPIC); MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION; TREATMENT OUTCOME; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG DESIGN; DRUG EFFECTS; ECONOMICS; MULTIDRUG RESISTANCE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

MYCOBACTERIUM TUBERCULOSIS COMPLEX;

ANTITUBERCULAR AGENTS; CLINICAL TRIALS AS TOPIC; DIARYLQUINOLINES; DRUG APPROVAL; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; NITROIMIDAZOLES; OXAZOLES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84891546754     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.13.122028     Document Type: Article

References (30)

1. World Health Organization [Internet]. WHO global tuberculosis report 2012. Geneva: WHO; 2012. Available from: http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf [accessed 29 September 2013].
2. Guidelines for the programmatic management of drug-resistant tuberculosis 2011 update. Geneva: World Health Organization; 2011 (WHO/HTM/TB/2011.6). Available from: http://apps.who.int/iris/bitstream/10665/44597/1/9789241501583_eng.pdf [accessed 29 September 2013].
3. DR-TB drugs under the microscope: sources and prices for drug resistant TB medications. 2nd ed. Geneva: Médecins Sans Frontières & International Union Against Tuberculosis and Lung Disease; 2012.
4. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN et al.; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012;9:e1001300. doi: http://dx.doi.org/10.1371/journal.pmed.1001300 PMID:22952439.
5. World Health Organization [Internet]. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. Geneva: WHO; 2013. Available from: http://www.who.int/iris/bitstream/10665/84879/1/9789241505482_eng.pdf [accessed 23 August 2013].
6. Otsuka receives opinion from CHMP on delamanid. Geneva: Otsuka Pharmaceutical Co., Ltd.; 2013. Available from: http://www.otsuka.co.jp/en/company/release/2013/0726_01.html [accessed 23 August 2013].
7. European Medicines Agency [Internet]. Refusal of the marketing authorisation for delamanid (delamanid). London: EMA; 2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002552/WC500146651.pdf [accessed 14 October 2013].
8. Gopal M, Padayatchi N, Metcalfe JZ, O'Donnell MR. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis [review]. Int J Tuberc Lung Dis 2013;17:1001-7. doi: http://dx.doi.org/10.5588/ijtld.12.0144 PMID:23541151.
9. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012;367:1508-18. doi: http://dx.doi.org/10.1056/NEJMoa1201964 PMID:23075177.
10. Dey T, Brigden G, Cox H, Shubber Z, Cooke G, Ford N. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2013;68:284-93. doi: http://dx.doi.org/10.1093/jac/dks389 PMID:23054996.
11. Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012;380(Issue 9846):986-93. doi: http://dx.doi.org/10.1016/S0140-6736(12)61080-0 PMID:22828481.
12. Williams K, Minkowski A, Amoabeng O, Peloquin CA, Taylor D, Andries K et al. Sterilizing activities of novel combinations lacking first-and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 2012;56:3114-20. doi: http://dx.doi.org/10.1128/AAC.00384-12 PMID:22470112.
13. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009;360:2397-405. doi: http://dx.doi.org/10.1056/NEJMoa0808427 PMID:19494215.
14. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012;366:2151-60. doi: http://dx.doi.org/10.1056/NEJMoa1112433 PMID:22670901.
15. Wallis RS, Jakubiec W, Mitton-Fry M, Ladutko L, Campbell S, Paige D et al. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PLoS One 2012;7:e30479. doi: http://dx.doi.org/10.1371/journal.pone.0030479 PMID:22279595.
16. Dalton T, Cegielski P, Akksilp S, Asencios L, Campos Caoili J, Cho SN et al.; Global PETTS Investigators. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 2012;380:1406-17. doi: http://dx.doi.org/10.1016/S0140-6736(12)60734-X PMID:22938757.
17. Nyang'wa BT, Brigden G, du Cros P, Shanks L. Resistance to second-line drugs in multidrug-resistant tuberculosis. Lancet 2013;381:625. doi: http://dx.doi.org/10.1016/S0140-6736(13)60341-4 PMID:23439097.
18. De March Ayuela P, Turell Gumá J. Resultados obtenidos mediante regímentes de asociacion con dos o tres drogas secundarias en el retratamiento del tuberculoso pulmonar crónico. Rev Clin Esp 1968;109:117-26. Spanish PMID:4904020.
19. Caminero JA; World Health Organization; American Thoracic Society; British Thoracic Society. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis 2006;10:829-37. PMID:16898365.
20. Van Deun A, Maug AKJ, Salim MAH, Das PK, Sarker MR, Daru P et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010;182:684-92. doi: http://dx.doi.org/10.1164/rccm.201001-0077OC PMID:20442432.
21. Dalton T, Cegielski P, Akksilp S, Asencios L, Campos Caoili J, Cho S-N et al.; Global PETTS Investigators. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 2012;380:1406-17. doi: http://dx.doi.org/10.1016/S0140-6736(12)60734-X PMID:22938757.
22. Sturdy A, Goodman A, José RJ, Loyse A, O'Donoghue M, Kon OM et al. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J Antimicrob Chemother 2011;66:1815-20. doi: http://dx.doi.org/10.1093/jac/dkr221 PMID:21642291.
23. Duggal P, Sarkar M. Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up. BMC Ear Nose Throat Disord 2007;7:5. doi: http://dx.doi.org/10.1186/1472-6815-7-5 PMID:17997841.
24. Nathanson E, Gupta R, Huamani P, Leimane V, Pasechnikov AD, Tupasi TE et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 2004;8:1382-4. PMID:15581210.
25. Törün T, Güngör G, Ozmen I, Bölükbaşi Y, Maden E, Biçakçi B et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005;9:1373-7. PMID:16468160.
26. Zhang Q, Liu Y, Tang S, Sha W, Xiao H. Clinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in China. Cell Biochem Biophys 2013. Apr 2 [Epub ahead of print]. doi: http://dx.doi.org/10.1007/s12013-013-9589-5 PMID:23546935.
27. Highlights of prescribing information. Silver Spring: United States Food and Drug Agency; 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/204384s000lbl.pdf [accessed 23 August 2013].
28. Gelband H. Regimens of less than six months for treating tuberculosis. Cochrane Database Syst Rev 2000. CD001362. doi: http://dx.doi.org/10.1002/14651858.CD001362 PMID:10796641.
29. Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013;41:1393-400. doi: http://dx.doi.org/10.1183/09031936.00125812 PMID:23018916.
30. World Health Organization [Internet]. WHO model list of essential medicines application-Bedaquiline 100 mg tablet. Geneva: WHO; 2013. Available from: http://www.who.int/selection_medicines/committees/expert/19/applications/Bedaquiline_6_2_4_A_Ad.pdf [accessed 29 September 2013].